Annual CFF
$211.91 M
-$555.69 M-72.39%
31 December 2023
Summary:
Biohaven Pharmaceutical Holding annual cash flow from financing activities is currently $211.91 million, with the most recent change of -$555.69 million (-72.39%) on 31 December 2023. During the last 3 years, it has risen by +$59.67 million (+39.19%). BHVN annual CFF is now -72.39% below its all-time high of $767.60 million, reached on 31 December 2022.BHVN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$80.38 M
-$240.75 M-74.97%
30 September 2024
Summary:
Biohaven Pharmaceutical Holding quarterly cash flow from financing activities is currently $80.38 million, with the most recent change of -$240.75 million (-74.97%) on 30 September 2024. Over the past year, it has increased by +$120.03 million (+302.68%). BHVN quarterly CFF is now -84.84% below its all-time high of $530.18 million, reached on 31 December 2022.BHVN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$650.16 M
+$120.03 M+22.64%
30 September 2024
Summary:
Biohaven Pharmaceutical Holding TTM cash flow from financing activities is currently $650.16 million, with the most recent change of +$120.03 million (+22.64%) on 30 September 2024. Over the past year, it has increased by +$153.30 million (+30.85%). BHVN TTM CFF is now -17.58% below its all-time high of $788.82 million, reached on 01 December 2020.BHVN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BHVN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -72.4% | +302.7% | +30.9% |
| 3 y3 years | +39.2% | - | - |
| 5 y5 years | -37.8% | +2825.9% | +49.6% |
BHVN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -72.4% | +53.1% | -84.8% | +302.7% | -15.7% | +2722.7% |
| 5 y | 5 years | -72.4% | +53.1% | -84.8% | +302.7% | -17.6% | +2722.7% |
| alltime | all time | -72.4% | +3886.2% | -84.8% | +302.7% | -17.6% | >+9999.0% |
Biohaven Pharmaceutical Holding Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $80.38 M(-75.0%) | $650.16 M(+22.6%) |
| June 2024 | - | $321.12 M(+9281.3%) | $530.13 M(+181.0%) |
| Mar 2024 | - | $3.42 M(-98.6%) | $188.66 M(-11.0%) |
| Dec 2023 | $211.91 M(-72.4%) | $245.24 M(-718.4%) | $211.91 M(-57.3%) |
| Sept 2023 | - | -$39.66 M(+95.0%) | $496.85 M(-25.2%) |
| June 2023 | - | -$20.34 M(-176.3%) | $664.05 M(-13.9%) |
| Mar 2023 | - | $26.67 M(-95.0%) | $771.23 M(+0.5%) |
| Dec 2022 | $767.60 M(+454.4%) | $530.18 M(+315.7%) | $767.60 M(+223.3%) |
| Sept 2022 | - | $127.54 M(+46.9%) | $237.42 M(+116.1%) |
| June 2022 | - | $86.84 M(+277.0%) | $109.87 M(+377.0%) |
| Mar 2022 | - | $23.03 M(+18.9%) | $23.03 M(-97.1%) |
| Dec 2021 | $138.45 M(-9.1%) | - | - |
| Dec 2020 | $152.24 M(-65.0%) | - | - |
| Dec 2020 | - | $19.37 M(-95.9%) | $788.82 M(+2.2%) |
| Sept 2020 | - | $472.31 M(+3988.9%) | $772.20 M(+139.8%) |
| June 2020 | - | $11.55 M(-96.0%) | $322.05 M(-55.2%) |
| Mar 2020 | - | $285.60 M(>+9900.0%) | $719.13 M(+65.5%) |
| Dec 2019 | $434.59 M | - | - |
| Dec 2019 | - | $2.75 M(-87.6%) | $434.59 M(-23.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | $22.15 M(-94.6%) | $567.86 M(+3.9%) |
| June 2019 | - | $408.63 M(>+9900.0%) | $546.31 M(+91.3%) |
| Mar 2019 | - | $1.06 M(-99.2%) | $285.52 M(-16.1%) |
| Dec 2018 | $340.46 M(+62.3%) | - | - |
| Dec 2018 | - | $136.01 M(>+9900.0%) | $340.46 M(+66.2%) |
| Sept 2018 | - | $602.00 K(-99.6%) | $204.85 M(+3.8%) |
| June 2018 | - | $147.85 M(+164.0%) | $197.26 M(-13.4%) |
| Mar 2018 | - | $56.00 M(>+9900.0%) | $227.81 M(+8.6%) |
| Dec 2017 | $209.76 M(+283.0%) | - | - |
| Dec 2017 | - | $397.00 K(-105.7%) | $209.76 M(-15.4%) |
| Sept 2017 | - | -$6.99 M(-103.9%) | $247.96 M(-5.1%) |
| June 2017 | - | $178.40 M(+370.1%) | $261.27 M(+191.2%) |
| Mar 2017 | - | $37.95 M(-1.7%) | $89.73 M(+63.9%) |
| Dec 2016 | $54.76 M(+930.1%) | - | - |
| Dec 2016 | - | $38.60 M(+510.6%) | $54.76 M(+238.9%) |
| Sept 2016 | - | $6.32 M(-7.8%) | $16.16 M(+64.3%) |
| June 2016 | - | $6.86 M(+130.2%) | $9.84 M(+230.2%) |
| Mar 2016 | - | $2.98 M | $2.98 M |
| Dec 2015 | $5.32 M | - | - |
FAQ
- What is Biohaven Pharmaceutical Holding annual cash flow from financing activities?
- What is the all time high annual CFF for Biohaven Pharmaceutical Holding?
- What is Biohaven Pharmaceutical Holding annual CFF year-on-year change?
- What is Biohaven Pharmaceutical Holding quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Biohaven Pharmaceutical Holding?
- What is Biohaven Pharmaceutical Holding quarterly CFF year-on-year change?
- What is Biohaven Pharmaceutical Holding TTM cash flow from financing activities?
- What is the all time high TTM CFF for Biohaven Pharmaceutical Holding?
- What is Biohaven Pharmaceutical Holding TTM CFF year-on-year change?
What is Biohaven Pharmaceutical Holding annual cash flow from financing activities?
The current annual CFF of BHVN is $211.91 M
What is the all time high annual CFF for Biohaven Pharmaceutical Holding?
Biohaven Pharmaceutical Holding all-time high annual cash flow from financing activities is $767.60 M
What is Biohaven Pharmaceutical Holding annual CFF year-on-year change?
Over the past year, BHVN annual cash flow from financing activities has changed by -$555.69 M (-72.39%)
What is Biohaven Pharmaceutical Holding quarterly cash flow from financing activities?
The current quarterly CFF of BHVN is $80.38 M
What is the all time high quarterly CFF for Biohaven Pharmaceutical Holding?
Biohaven Pharmaceutical Holding all-time high quarterly cash flow from financing activities is $530.18 M
What is Biohaven Pharmaceutical Holding quarterly CFF year-on-year change?
Over the past year, BHVN quarterly cash flow from financing activities has changed by +$120.03 M (+302.68%)
What is Biohaven Pharmaceutical Holding TTM cash flow from financing activities?
The current TTM CFF of BHVN is $650.16 M
What is the all time high TTM CFF for Biohaven Pharmaceutical Holding?
Biohaven Pharmaceutical Holding all-time high TTM cash flow from financing activities is $788.82 M
What is Biohaven Pharmaceutical Holding TTM CFF year-on-year change?
Over the past year, BHVN TTM cash flow from financing activities has changed by +$153.30 M (+30.85%)